Efficacy, acceptability, and tolerability of antidepressant treatments for patients with post-stroke depression: A network meta-analysis

Brazilian Journal of Medical and Biological Research

Volumn 51, Issue 7, 2018, Pages

  Qin, B ^a   Chen, H ^a   Gao, W ^a   Zhao, L B ^b   Zhao, M J ^c,d   Qin, H X ^a   Chen, W ^a   Chen, L ^a   Yang, M X ^a  

^a GUANGXI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c XINXIANG MEDICAL UNIVERSITY   (China)

^d Henan Mental Hospital   (China)

Author keywords

Antidepressants; Network meta analysis; Post stroke depression; Randomized controlled trials

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DOXEPIN; DULOXETINE; FLUOXETINE; IMIPRAMINE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; ASSESSMENT OF HUMANS; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG TOLERABILITY; HAMILTON DEPRESSION RATING SCALE; HUMAN; META ANALYSIS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NETWORK META-ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POST-STROKE DEPRESSION; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); ZUNG DEPRESSION SCALE; CEREBROVASCULAR ACCIDENT; COMPLICATION; DEPRESSION; FEMALE; MALE; PLACEBO EFFECT; PSYCHOLOGY; REPRODUCIBILITY; TIME FACTOR; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; NETWORK META-ANALYSIS; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 85046804078     PISSN: None     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20187218     Document Type: Article

References (40)

1. Kotila M, Numminen H, Waltimo O, Kaste M. Post-stroke depression and functional recovery in a population-based stroke register. Eur J Neurol 1999; 6: 309-312, doi: 10.1046/j.1468-1331.1999.630309.x.
2. Dam M, Tonin P, De Boni A, Pizzolato G, Casson S, Ermani M, et al. Effects of fluoxetine and maprotiline on functional recovery in post-stroke hemiplegics patients undergoing rehabilitation therapy. Stroke 1996; 27: 1211-1214, doi: 10.1161/01.STR.27.7.1211.
3. Kong Y, Dong W, Liu CF. Fluoxetine for post-stroke depression: a randomized controlled clinical trial. Neu Regen Res 2007; 2: 162-165, doi: 10.1016/S1673-5374(07)60036-X.
4. Hackett ML, Anderson CS, House AO. Management of depression after stroke: a systematic review of pharmacological therapies. Stroke 2005; 36: 1098-1103, doi: 10.1161/01.STR.0000162388.67745.8d.
5. Chen Y, Guo JJ, Zhan S, Patel NC. Treatment effects of antidepressants in patients with post-stroke depression: a meta-analysis. Ann Pharmacother 2006; 40: 2115-2122, doi: 10.1345/aph.1H389.
6. Hackett ML, Anderson CS, House A, Xia J. Interventions for treating depression after stroke. Cochrane Database Syst Rev 2008; 4: CD003437.
7. Robinson RG. The clinical neuropsychiatry of stroke. New York: Cambridge University Press; 2006.
8. Hackett ML, Anderson CS, House AO. Interventions for treating depression after stroke. Stroke 2009; 40: e487-488, doi: 10.1161/STROKEAHA.109.547059.
9. Price A, Rayner L, Okon-Rocha E, Evans A, Valsraj K, Higginson IJ, et al. Antidepressants for the treatment of depression in neurological disorders: a systematic review and meta-analysis of randomised controlled trials. J Neurol Neurosurg Psychiatry 2011; 82: 914-923, doi: 10.1136/jnnp.2010.230862.
10. Xu XM, Zou DZ, Shen LY, Liu Y, Zhou XY, Pu JC, et al. Efficacy and feasibility of antidepressant treatment in patients with post-stroke depression. Medicine 2016; 95: e5349, doi: 10.1097/MD.0000000000005349.
11. Tan S, Huang X, Ding L, Hong H. Efficacy and safety of citalopram in treating post-stroke depression: a meta-analysis. Eur Neurol 2015; 74: 188-201, doi: 10.1159/000441446.
12. Higgins JP, Whitehead A. Borrowing strength from external trials in a meta-analysis. Stat Med 1996; 15: 2733-2749, doi: 10.1002/(SICI)1097-0258(19961230)15:24o2733::AIDSIM56243.0.CO;2-0.
13. Xu Y, Bai SJ, Lan XH, Qin B, Huang T, Xie P. Randomized controlled trials of serotonin-norepinephrine reuptake inhibitor in treating major depressive disorder in children and adolescents: a meta-analysis of efficacy and acceptability. Braz J Med Biol Res 2016; 49: e4806, doi: 10.1590/1414-431X20164806.
14. Cipriani A, Zhou X, Del Giovane C, Hetrick SE, Qin B, Whittington C, et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet 2016; 388: 881-890, doi: 10.1016/S0140-6736(16)30385-3.
15. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004; 23: 3105-3124, doi: 10.1002/sim.1875.
16. Salanti G, Ades AE, Ioannides JP. Graphical methods and numerical summaries for presenting results from multipletreatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011; 64: 163-171, doi: 10.1016/j.jclinepi.2010. 03.016.
17. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making 2013; 33: 607-617, doi: 10.1177/0272989X12458724.
18. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PloS One 2013; 8: e76654, doi: 10.1371/journal.pone.0076654.
19. Jackson D, Barrett JK, Rice S, White IR, Higgins JP. A design-by-treatment interaction model for network metaanalysis with random inconsistency effects. Stat Med 2014; 33: 3639-3654, doi: 10.1002/sim.6188.
20. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010; 29: 932-944, doi: 10.1002/sim.3767.
21. Andersen G, Vestergaard K, Lauritzen L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994; 25: 1099-1104, doi: 10.1161/01.STR.25.6.1099.
22. Chen W, Wang G, Chen X, Sheng Y, Zhu H. Effects of paroxetine on function recovery in patients with poststroke depression. Chin J Clin Rehabilit 2002; 13: 2014-2015.
23. Fruehwald S, Gatterbauer E, Rehak P, Baumhackl U. Early fluoxetine treatment of post-stroke depression: a three months double-blind placebo-controlled study with an open-label longterm follow up. J Neurol 2003; 250: 347-351, doi: 10.1007/s00415-003-1014-3.
24. Karaiskos D, Tzavellas E, Spengos K, Vassilopoulou S, Paparrigopoulos T. Duloxetine versus citalopram and sertraline in the treatment of poststroke depression, anxiety, and fatigue. J Neuropsychiatry Clin Neurosci 2012; 24: 349-353, doi: 10.1176/appi.neuropsych.11110325.
25. Li LT, Wang SH, Ge HY, Chen J, Yue SW, Yu M. The beneficial effects of the herbal medicine free and easy wanderer plus (FEWP) and fluoxetine on post-stroke depression. J Altern Complement Med 2008; 14: 841-846, doi: 10.1089/acm.2008.0010.
26. Lipsey JR, Robinson RG, Pearlson GD, Rao K, Price TR. Nortriptyline treatment of post-stroke depression: a doubleblind study. Lancet 1984; 1: 297-300, doi: 10.1016/S0140-6736(84)90356-8.
27. Murray V, von Arbin M, Bartfai A, Berggren AL, Landtblom AM, Lundmark J, et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. J Clin Psychiatry 2005; 66: 708-716, doi: 10.4088/JCP.v66n0606.
28. Ponzio F, Marini G, Riva E. The efficacy of paroxetine in some kinds of “critical” patients. Eur Neuropsychopharmacol 2001; 11 (Suppl 2): S49-S50 (Abstract P.1.29).
29. Raffaele R, Rampello L, Vecchio I, Tornali C, Malaguarnera M. Trazodone therapy of the poststroke depression. Arch Gerontol Geriatr 1996; 22 (Suppl 1): 217-220, doi: 10.1016/0167-4943(96)86939-1.
30. Reding MJ, Orto LA, Winter SW, Fortuna IM, Di Ponte P, McDowell FH. Antidepressant therapy after stroke: a doubleblind trial. Arch Neurol 1986; 43: 763-765, doi: 10.1001/archneur.1986.00520080011011.
31. Robinson RG, Schultz SK, Castillo C, Kopel T, Kosier JT, Newman RM, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry 2000; 157: 351-359, doi: 10.1176/appi.ajp.157.3.351.
32. Tzavellas E, Karaiskos D, Spengos K, Economou E, Papadimitriou GN, Liappas I, et al. Duloxetine versus sertraline in the treatment of post-stroke depression. Eur Neuropsychopharmacol 2010; 20 (Suppl 3): S387 (Abstract P.2.c.034), doi: 10.1016/S0924-977X(10)70549-6.
33. Wiart L, Petit H, Joseph PA, Mazaux JM, Barat M. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 2000; 31: 1829-1832, doi: 10.1161/01.STR.31.8.1829.
34. Ye L, Wang Y, Wang H, Liang D. Effect of Paxil and berhomine on poststroke anxiety-depression and neurological recovery. Chin J Clin Rehabilit 2006; 6: 153-155.
35. Biau DJ, Kernéis S, Porcher R. Statistics in brief: the importance of sample size in the planning and interpretation of medical research. Clin Orthop Relat Res 2008; 466: 2282-2288, doi: 10.1007/s11999-008-0346-9.
36. Horváth S, Karányi Z, Harcos P, Nagy Z, Németh G, Andor G. Clinical effectiveness and safety of paroxetine in poststroke depression: results from a phase 4, open label, multicenter clinical trial with 26 weeks of follow-up. Orv Hetil 2006; 147: 2397-2404.
37. Huwiler-Müntener K, Jüni P, Junker C, Egger M. Quality of reporting of randomized trials as a measure of methodologic quality. JAMA 2002; 287: 2801-2804, doi: 10.1001/jama. 287.21.2801.
38. Sandner-Kiesling A, Leyendecker P, Hopp M, Tarau L, Lejcko J, Meissner W, et al. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract 2010; 64: 763-774, doi: 10.1111/j.1742-1241.2010.02360.x.
39. Webster LR, Slevin KA, Narayana A, Earl CQ, Yang R. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes. Pain Med 2013; 14: 1332-1345, doi: 10.1111/pme. 12184.
40. Nuckols TK, Anderson L, Popescu I, Diamant AL, Doyle B, Di Capua P, et al. Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med 2014; 160: 38-47.